vs
Side-by-side financial comparison of LIFECORE BIOMEDICAL, INC. \DE\ (LFCR) and PETMED EXPRESS INC (PETS). Click either name above to swap in a different company.
PETMED EXPRESS INC is the larger business by last-quarter revenue ($40.7M vs $31.1M, roughly 1.3× LIFECORE BIOMEDICAL, INC. \DE\). PETMED EXPRESS INC runs the higher net margin — -26.0% vs -32.1%, a 6.2% gap on every dollar of revenue. On growth, LIFECORE BIOMEDICAL, INC. \DE\ posted the faster year-over-year revenue change (-4.5% vs -23.3%). LIFECORE BIOMEDICAL, INC. \DE\ produced more free cash flow last quarter ($25.0K vs $-9.2M). Over the past eight quarters, LIFECORE BIOMEDICAL, INC. \DE\'s revenue compounded faster (-0.1% CAGR vs -20.9%).
LIFECORE BIOMEDICAL, INC. is a biomedical firm focused on developing and manufacturing high-quality hyaluronic acid-based biomaterials. It operates three core segments: medical application products, pharmaceutical solutions, and personal care ingredients, with main markets spanning North America, Europe and the Asia-Pacific, supplying to leading medical device, pharmaceutical and cosmetic brand partners.
PetMed Express, Inc., also known as PetMeds, is an online pet pharmacy based in the United States. It is publicly traded and sells prescription and non-prescription pet medication.
LFCR vs PETS — Head-to-Head
Income Statement — Q2 FY2026 vs Q3 FY2026
| Metric | | |
|---|---|---|
| Revenue | $31.1M | $40.7M |
| Net Profit | $-10.0M | $-10.6M |
| Gross Margin | 25.0% | 23.3% |
| Operating Margin | -9.9% | -25.7% |
| Net Margin | -32.1% | -26.0% |
| Revenue YoY | -4.5% | -23.3% |
| Net Profit YoY | -52.0% | -1392.6% |
| EPS (diluted) | $-0.29 | $-0.50 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $40.7M | ||
| Q3 25 | $31.1M | $44.4M | ||
| Q2 25 | — | $51.2M | ||
| Q1 25 | $35.2M | $50.8M | ||
| Q4 24 | $32.6M | $52.0M | ||
| Q3 24 | $24.7M | $58.0M | ||
| Q2 24 | — | $66.2M | ||
| Q1 24 | $35.7M | $65.1M |
| Q4 25 | — | $-10.6M | ||
| Q3 25 | $-10.0M | $-8.5M | ||
| Q2 25 | — | $-34.2M | ||
| Q1 25 | $-14.8M | $-11.6M | ||
| Q4 24 | $-6.6M | $-707.0K | ||
| Q3 24 | $-16.2M | $2.3M | ||
| Q2 24 | — | $3.8M | ||
| Q1 24 | $15.6M | $-5.0M |
| Q4 25 | — | 23.3% | ||
| Q3 25 | 25.0% | 28.0% | ||
| Q2 25 | — | 28.1% | ||
| Q1 25 | 28.0% | 29.9% | ||
| Q4 24 | 34.0% | 31.0% | ||
| Q3 24 | 21.8% | 32.3% | ||
| Q2 24 | — | 28.8% | ||
| Q1 24 | 33.3% | 29.3% |
| Q4 25 | — | -25.7% | ||
| Q3 25 | -9.9% | -18.9% | ||
| Q2 25 | — | -66.7% | ||
| Q1 25 | -25.7% | -11.9% | ||
| Q4 24 | -6.0% | -0.9% | ||
| Q3 24 | -46.9% | 1.0% | ||
| Q2 24 | — | 6.6% | ||
| Q1 24 | -2.5% | -5.9% |
| Q4 25 | — | -26.0% | ||
| Q3 25 | -32.1% | -19.2% | ||
| Q2 25 | — | -66.7% | ||
| Q1 25 | -42.0% | -22.9% | ||
| Q4 24 | -20.2% | -1.4% | ||
| Q3 24 | -65.7% | 4.0% | ||
| Q2 24 | — | 5.7% | ||
| Q1 24 | 43.8% | -7.7% |
| Q4 25 | — | $-0.50 | ||
| Q3 25 | $-0.29 | $-0.41 | ||
| Q2 25 | — | $-1.65 | ||
| Q1 25 | $-0.47 | $-0.56 | ||
| Q4 24 | $-0.25 | $-0.03 | ||
| Q3 24 | $-0.53 | $0.11 | ||
| Q2 24 | — | $0.18 | ||
| Q1 24 | $0.42 | $-0.24 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $18.9M | $26.9M |
| Total DebtLower is stronger | $136.0M | — |
| Stockholders' EquityBook value | $-10.5M | $32.8M |
| Total Assets | $235.2M | $88.0M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $26.9M | ||
| Q3 25 | $18.9M | $36.1M | ||
| Q2 25 | — | $41.1M | ||
| Q1 25 | $5.4M | $54.7M | ||
| Q4 24 | $9.5M | $50.1M | ||
| Q3 24 | — | $52.0M | ||
| Q2 24 | — | $46.0M | ||
| Q1 24 | — | $55.3M |
| Q4 25 | — | — | ||
| Q3 25 | $136.0M | — | ||
| Q2 25 | — | — | ||
| Q1 25 | $124.9M | — | ||
| Q4 24 | $111.3M | — | ||
| Q3 24 | $106.3M | — | ||
| Q2 24 | — | — | ||
| Q1 24 | $97.1M | — |
| Q4 25 | — | $32.8M | ||
| Q3 25 | $-10.5M | $43.1M | ||
| Q2 25 | — | $51.5M | ||
| Q1 25 | $2.2M | $85.1M | ||
| Q4 24 | $15.4M | $96.2M | ||
| Q3 24 | $-3.9M | $96.4M | ||
| Q2 24 | — | $93.5M | ||
| Q1 24 | $17.7M | $96.7M |
| Q4 25 | — | $88.0M | ||
| Q3 25 | $235.2M | $100.3M | ||
| Q2 25 | — | $109.8M | ||
| Q1 25 | $237.7M | $148.7M | ||
| Q4 24 | $255.4M | $144.8M | ||
| Q3 24 | $246.8M | $146.0M | ||
| Q2 24 | — | $152.7M | ||
| Q1 24 | $246.2M | $169.9M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | 56.05× | — | ||
| Q4 24 | 7.20× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | 5.49× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $1.8M | $-9.2M |
| Free Cash FlowOCF − Capex | $25.0K | $-9.2M |
| FCF MarginFCF / Revenue | 0.1% | -22.7% |
| Capex IntensityCapex / Revenue | 5.6% | 0.1% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-16.8M | $-23.0M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $-9.2M | ||
| Q3 25 | $1.8M | $-2.2M | ||
| Q2 25 | — | $-12.3M | ||
| Q1 25 | $1.2M | $7.0M | ||
| Q4 24 | $-6.1M | $-1.2M | ||
| Q3 24 | $-613.0K | $7.4M | ||
| Q2 24 | — | $-8.5M | ||
| Q1 24 | $-1.4M | $7.1M |
| Q4 25 | — | $-9.2M | ||
| Q3 25 | $25.0K | $-4.8M | ||
| Q2 25 | — | $-13.6M | ||
| Q1 25 | $-4.3M | $4.6M | ||
| Q4 24 | $-8.6M | $-1.9M | ||
| Q3 24 | $-4.0M | $6.1M | ||
| Q2 24 | — | $-9.2M | ||
| Q1 24 | $-7.8M | $5.9M |
| Q4 25 | — | -22.7% | ||
| Q3 25 | 0.1% | -10.8% | ||
| Q2 25 | — | -26.5% | ||
| Q1 25 | -12.1% | 9.1% | ||
| Q4 24 | -26.3% | -3.7% | ||
| Q3 24 | -16.3% | 10.6% | ||
| Q2 24 | — | -13.9% | ||
| Q1 24 | -21.8% | 9.0% |
| Q4 25 | — | 0.1% | ||
| Q3 25 | 5.6% | 5.9% | ||
| Q2 25 | — | 2.5% | ||
| Q1 25 | 15.5% | 4.7% | ||
| Q4 24 | 7.5% | 1.5% | ||
| Q3 24 | 13.9% | 2.2% | ||
| Q2 24 | — | 1.0% | ||
| Q1 24 | 17.8% | 1.9% |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 3.18× | ||
| Q2 24 | — | -2.27× | ||
| Q1 24 | -0.09× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
LFCR
| Transferred At Point In Time | $26.6M | 85% |
| Transferred Over Time | $4.5M | 15% |
PETS
| Reorder | $34.0M | 84% |
| New Order | $5.0M | 12% |
| Membership Fees | $1.6M | 4% |
